Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A7 | Q99884 | 18/20 | 0.60 |
| ▸ | SMO | Q99835 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3575473 | 1.00 | SLC6A7 (0.60) | SLC6A7SMOMEN1KMT2AALDH1A1 | |
| SCHEMBL4754888 | 0.89 | SLC6A7 (0.63) | SLC6A7SMOALDH1A1TSHR | |
| SCHEMBL4754891 | 0.89 | SLC6A7 (0.63) | SLC6A7SMOALDH1A1TSHR | |
| SCHEMBL3575986 | 0.89 | SLC6A7 (0.62) | SLC6A7MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL3575992 | 0.89 | SLC6A7 (0.62) | SLC6A7MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL3574220 | 0.87 | SLC6A7 (0.70) | SLC6A7MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL3574215 | 0.87 | SLC6A7 (0.70) | SLC6A7MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL3585370 | 0.85 | SLC6A7 (0.63) | SLC6A7SMOALDH1A1TSHR | |
| SCHEMBL3585367 | 0.85 | SLC6A7 (0.63) | SLC6A7SMOALDH1A1TSHR | |
| SCHEMBL3585156 | 0.85 | SLC6A7 (0.60) | SLC6A7SMOALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060258672-A1 | Multicyclic compounds and methods of their use | LEXICON PHARMACEUTICALS, INC. | 2006-11-16 | — | — | US | claimed |
| US-8772291-B2 | Multicyclic compounds and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| EP-1893212-B1 | MULTICYCLIC COMPOUNDS AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS INC (US) | 2013-10-16 | — | — | EP | disclosed |
| US-20100081691-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. (US) | 2010-04-01 | — | — | US | disclosed |
| US-20090306100-A1 | METHODS OF TREATING SCHIZOPHRENIA | LEXICON PHARMACEUTICALS, INC. | 2009-12-10 | — | — | US | disclosed |
| US-20080153811-A1 | methods for treating, managing and preventing cognitive impairment associated with various diseases and disorders, age-associated memory impairment, and dementia. | LEXICON PHARMACEUTICALS, INC. | 2008-06-26 | — | — | US | disclosed |
| US-20060258672-A1 | Multicyclic compounds and methods of their use | LEXICON PHARMACEUTICALS, INC. | 2006-11-16 | — | — | US | disclosed |
| US-20060258691-A1 | Methods and compositions for improving cognition | LEXICON PHARMACEUTICALS, INC. | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081691-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF THEIR USE | GRIN2C, CHAT, COMT | SLC6A7 1113/4885SMO 3497/4885MEN1 1568/4885 |
| US-20080153811-A1 | methods for treating, managing and preventing cognitive impairment associated with various diseases and disorders, age-associated memory impairment, and dementia. | CHAT, PSEN2, PSEN1 | SLC6A7 1024/4885SMO 3734/4885MEN1 2823/4885 |
| US-20090306100-A1 | METHODS OF TREATING SCHIZOPHRENIA | CHAT, GAP43, GRIN2A | SLC6A7 746/4885SMO 3116/4885MEN1 4522/4885 |
| US-20060258691-A1 | Methods and compositions for improving cognition | PSEN1, PSEN2, APP | SLC6A7 2686/4885SMO 1041/4885MEN1 1620/4885 |
| US-20060258672-A1 | Multicyclic compounds and methods of their use | GRIN2C, CHAT, COMT | SLC6A7 1113/4885SMO 3497/4885MEN1 1568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.